Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 10:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 84 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: C. Difficile Infection Clear all
Completed Phase 1 Interventional

Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile

NCT03827447
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Vancomycin Oral Capsule, Placebo Oral Capsule
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Jun 26, 2026, 10:47 PM EDT
Not yet recruiting Phase 1 Interventional

Xylitol Use for Decolonization of C. Difficile in Patients With IBD

NCT05852587
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Clostridioides Difficile Infection
Interventions
Xylitol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jun 26, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

NCT03244644
View directory record Official record
Conditions
Clostridium Difficile Infection (CDI)
Interventions
RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence)
Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
60
States / cities
Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Jun 26, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease

NCT00350298
View directory record Official record
Conditions
Clostridium Infections
Interventions
GS-CDA1/MDX-1388, normal saline
Biological
Lead sponsor
MassBiologics
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
22
States / cities
Los Angeles, California • Oakland, California • Newark, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Jun 26, 2026, 10:47 PM EDT
Completed No phase listed Observational

C.Difficile Observational Study

NCT06277999
View directory record Official record
Conditions
Clostridium Infections
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
7
States / cities
Sacramento, California • Hamden, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jun 26, 2026, 10:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pathogenic Mechanisms in C Diff Infection and Colitis

NCT01930032
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Jun 26, 2026, 10:47 PM EDT
Completed Phase 2 Interventional

Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT): A Feasibility Clinical Trial

NCT01782755
View directory record Official record
Conditions
Ventilator Associated Pneumonia (VAP), Other Infections, Antibiotic-Associated Diarrhea, C-Difficile, Duration of Mechanical Ventilation, Length of ICU Stay, Length of Hospital Stay, ICU and Hospital Mortality
Interventions
L. rhamnosus GG - Probiotic, Placebo - Microcrystalline Cellulose
Drug · Other
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jun 26, 2026, 10:47 PM EDT
Completed Phase 4 Interventional

Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics

NCT03466502
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Oral Vancomycin
Drug
Lead sponsor
University of Nevada, Reno
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Jun 26, 2026, 10:47 PM EDT
Completed Not applicable Interventional Results available

Safety of Stool Transplant for Patients With Difficult to Treat C. Difficile Infection

NCT02770326
View directory record Official record
Conditions
C. Difficile Infection, Cancer
Interventions
Fecal Microbiota Transplantation (FMT)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Jun 26, 2026, 10:47 PM EDT
Completed Phase 3 Interventional

A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea

NCT00106509
View directory record Official record
Conditions
Clostridium Enterocolitis, Pseudomembranous Colitis
Interventions
tolevamer potassium-sodium (GT267-004)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
99
States / cities
Phoenix, Arizona • Rogers, Arkansas • Burbank, California + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Jun 26, 2026, 10:47 PM EDT
Recruiting Not applicable Interventional

Pre-emptive Prevention for Patients at High Risk for Hospital-onset Clostridioides Difficile

NCT05389904
View directory record Official record
Conditions
C. Difficile
Interventions
Arm 1: Routine care, Arm 2: Preemptive C. difficile infection prevention bundle
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jun 26, 2026, 10:47 PM EDT
Not yet recruiting Phase 4 Interventional

Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease

NCT06794944
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Clostridioides Difficile Infection
Interventions
Vancomycin (POC), Fidaxomicin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Jun 26, 2026, 10:47 PM EDT
Recruiting No phase listed Observational

C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.

NCT07250724
View directory record Official record
Conditions
Clostridioides Difficile Infection Recurrence
Interventions
Participants that are undergoing standard of care antibiotic treatment for their second C. Diff infection will be followed for 8 weeks after completing antibiotic treatment.
Other
Lead sponsor
Bactolife A/S
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Atlanta, Georgia • Royal Oak, Michigan • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jun 26, 2026, 10:47 PM EDT
Completed No phase listed Observational

FQ Restriction for the Prevention of CDI

NCT03848689
View directory record Official record
Conditions
Clostridium Difficile, Clostridium Difficile Infection, C Difficile Colitis
Interventions
fluoroquinolone preprescription authorization, Control
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
5,871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Phoenix, Arizona • Moreno Valley, California • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Jun 26, 2026, 10:47 PM EDT
Recruiting Phase 2 Interventional

Stool Transplants to Treat Refractory Clostridium Difficile Colitis

NCT02127398
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
fecal microbiota
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Jun 26, 2026, 10:47 PM EDT
Terminated Phase 2 Interventional Results available

FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI

NCT02255305
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
FMT, Antimicrobials
Biological · Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Jun 26, 2026, 10:47 PM EDT
Recruiting Phase 2 Interventional

Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)

NCT04305769
View directory record Official record
Conditions
Clostridioides Difficile Infection, Clostridium Difficile Infection, Clostridium Difficile Diarrhea, Clostridia Difficile Colitis
Interventions
Alanyl-glutamine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 105 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Charlottesville, Virginia • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Jun 26, 2026, 10:47 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)

NCT03005379
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Fecal Microbiota Therapy (FMT), Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Jun 26, 2026, 10:47 PM EDT
Terminated Phase 3 Interventional Results available

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)

NCT05153499
View directory record Official record
Conditions
Recurrent C. Difficile Infection
Interventions
CP101, Placebo
Biological · Other
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
61
States / cities
Phoenix, Arizona • Mission Hills, California • Oakland, California + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Jun 26, 2026, 10:47 PM EDT
Terminated Phase 2 Interventional Results available

Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI)

NCT03298048
View directory record Official record
Conditions
Recurrent C. Difficile Infection
Interventions
Low fecal microbiota dose, Mid fecal microbiota dose, High fecal microbiota dose
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Jun 26, 2026, 10:47 PM EDT
Not listed Phase 2 Interventional

An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection

NCT03988855
View directory record Official record
Conditions
Clostridium Difficile (C. Difficile)
Interventions
DNV3837
Drug
Lead sponsor
Deinove
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Anniston, Alabama • Sacramento, California • Idaho Falls, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Jun 26, 2026, 10:47 PM EDT
Recruiting Phase 3 Interventional

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452
View directory record Official record
Conditions
Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
Interventions
VE303, Placebo
Biological
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
12 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 26, 2026, 10:47 PM EDT
Completed No phase listed Observational

Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody

NCT00304408
View directory record Official record
Conditions
Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions
Not listed
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2010 · Synced Jun 26, 2026, 10:47 PM EDT
Not listed Phase 1 Interventional

Reduction of C-Difficile Infection Using Stool Transplant

NCT02112279
View directory record Official record
Conditions
C-difficile
Interventions
Donor microbiota applied via colonoscopy.
Biological
Lead sponsor
Providence Holy Cross Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Mission Hills, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Jun 26, 2026, 10:47 PM EDT